# Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

> **NCT02893995** · PHASE4 · WITHDRAWN · sponsor: **United Therapeutics**

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Slow Dose Titration Group of Subcutaneous Treprostinil
- **DRUG:** Rapid Dose Titration Group of Subcutaneous Treprostinil

## Key facts

- **NCT ID:** NCT02893995
- **Lead sponsor:** United Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-02
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2017-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02893995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02893995, "Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02893995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*